A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Exclusion Criteria

• •1. Current of significant alcohol consumption (significant alcohol consumption is defined as more than 210 g/week in males and more than 140 g/week in females, on average)
• •2. Planned use of Contraindicated Medications from written ICF to end of treatment.
• •3. BMI \< 22 kg/m2 at Screening
• •4. Uncontrolled diabetes mellitus as defined by a HbA1c(NGSP) ≥ 8.0％ at Screening
• •5. eGFR \< 30 mL/min/1.73m2 or Dialysis patient
• •6. Cirrhosis
• •7. Biliary obstruction
• •8. Patients were excluded if they had evidence of other forms of liver disease shown by the following:
• •* Hepatitis B or Hepatitis C
• •* Autoimmune hepatitis（AIH）
• •* Primary biliary cirrhosis（PBC）
• •* Primary Sclerosing Cholangitis（PSC）
• •* Drug-induced liver injury
• •* hyperthyroidism, Wilson's disease, hemochromatosis, alpha-1-antitrypsin disease
• •9. Those with complicating malignant neoplasm or those judged to be at a high risk of recurrence
• •10. Patients with contraindications to MRI imaging
• •11. Patients who gave 200 mL or more of blood within 1 month before the administration of the study drug, or 400 mL or more of blood within 4 months before the administration of the study drug
• •12. Patients with a history of serious drug allergies (such as anaphylactic shock)
• •13. Pregnancy, breast feeding, planned pregnancy
• •14. Patients who were participating in another clinical study at the time of consent was obtained or who received study drugs other than the placebo less than 16 weeks before consent was obtained
• •15. Patients who have previously been administered pemafibrate
• •16. Patients who have been determined inappropriate by the investigator or subinvestigator